Default: Oncologist

ISSN: 1083-7159

Journal Home

Journal Guideline

Oncologist Q1 Unclaimed

AlphaMed Press United States
Unfortunately this journal has not been claimed yet. For this reason, some information may be unavailable.

Oncologist is a journal indexed in SJR in Medicine (miscellaneous) and Oncology with an H index of 164. It has a price of 1260 €. It has an SJR impact factor of 2,176 and it has a best quartile of Q1. It is published in English. It has an SJR impact factor of 2,176.

Oncologist focuses its scope in these topics and keywords: cancer, patients, metastatic, treatment, colorectal, weeks, cell, lung, therapy, european, ...

Type: Journal

Type of Copyright:

Languages: English

Open Access Policy:

Type of publications:

Publication frecuency: -

Price

1260 €

Inmediate OA

NPD

Embargoed OA

0 €

Non OA

Metrics

Oncologist

2,176

SJR Impact factor

164

H Index

459

Total Docs (Last Year)

900

Total Docs (3 years)

12983

Total Refs

4329

Total Cites (3 years)

788

Citable Docs (3 years)

4,33

Cites/Doc (2 years)

28,29

Ref/Doc

Aims and Scope


cancer, patients, metastatic, treatment, colorectal, weeks, cell, lung, therapy, european, cisplatin, phase, study, screening, agency, breast, advanced, factor, tumor, ii, refractory, review, human, strategies, survival, targeted, therapeutic,



Best articles by citations

Managing Pulmonary Toxicities Associated with Immunotherapy: A Case Discussion

View more

The Role of Capecitabine, an Oral, Enzymatically Activated Fluoropyrimidine, in the Treatment of Metastatic Breast Cancer

View more

Estimates of Young Breast Cancer Survivors at Risk for Infertility in the U.S.

View more

TELEPRO: Patient-Reported Carcinoid Syndrome Symptom Improvement Following Initiation of Telotristat Ethyl in the Real World

View more

Survival Gains from First-Line Systemic Therapy in Metastatic Non-Small Cell Lung Cancer in the U.S., 1990-2015: Progress and Opportunities

View more

FDA Benefit-Risk Assessment of Osimertinib for the Treatment of Metastatic Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor T790M Mutation

View more

FDA Drug Approval Summary: Alemtuzumab as Single-Agent Treatment for B-Cell Chronic Lymphocytic Leukemia

View more

Multidisciplinary Management of Breast Cancer During Pregnancy

View more

FDA Drug Approval Summary: Bevacizumab Plus FOLFOX4 as Second-Line Treatment of Colorectal Cancer

View more

Use of High-Cost Cancer Treatments in Academic and Nonacademic Practice

View more

Venous Thromboembolism in Patients with Sarcoma: A Retrospective Study

View more

Diagnostic Value of Next-Generation Sequencing in an Unusual Sphenoid Tumor

View more
SHOW MORE ARTICLES

Clinical Variant Classification: A Comparison of Public Databases and a Commercial Testing Laboratory

View more

Active Specific Immunotherapy Targeting the Wilms' Tumor Protein 1 (WT1) for Patients with Hematological Malignancies and Solid Tumors: Lessons from Early Clinical Trials

View more

Staging of Regional Nodes in AJCC Stage I and II Melanoma:

View more

Breast Camps for Awareness and Early Diagnosis of Breast Cancer in Countries With Limited Resources: A Multidisciplinary Model From Kenya

View more

A Comprehensive Review of Sequencing and Combination Strategies of Targeted Agents in Metastatic Colorectal Cancer

View more

Advance Directives, Hospitalization, and Survival Among Advanced Cancer Patients with Delirium Presenting to the Emergency Department: A Prospective Study

View more

Managing Vesicant Extravasations

View more

Purine Analogs for the Treatment of Low-Grade Lymphoproliferative Disorders

View more

Safety of Intravenous and Oral Bisphosphonates and Compliance With Dosing Regimens

View more

The CAIRO and FOCUS Studies: Which Lesson Is to Be Learned?

View more

The Goal of Cancer Treatment

View more

Src Inhibition Is Still a Relevant Target in Pancreatic Cancer

View more

Comments

No comments ... Be the first to comment!

FAQS